摘要
Alzheimer's disease (AD) is a neurodegenerative disorder with limited available drugs for treatment. Enhancing autophagy attenuates AD pathology in various AD model mice. Thus, development of potential drugs which enhance autophagy may bring beneficial effects in AD therapy. In the present study, we show clemastine, a firstgeneration histamine H1R antagonist and being originally marketed for the treatment of allergic rhinitis, ameliorates AD pathogenesis in APP/PS1 transgenic mice. Chronic treatment with clemastine orally reduced amyloid-beta (A beta) load, neuroinflammation and cognitive deficits of APP/PS1 transgenic mice. Clemastine decreases A beta generation via reducing the levels of BACE1, CTFs of APP. Mechanistically, clemastine enhances autophagy concomitant with a suppression of mTOR signaling. Therefore, we propose that clemastine attenuates AD pathology via enhancing mTOR-mediated autophagy.
学科与关键词
- Neuroprotective effect of astragalin via activating PI3K/Akt-mTOR-mediated autophagy on APP/PS1 miceYang, Cui-Zhu; Wang, Shu-Han; Zhang, Run-Heng; Lin, Jia-Hong; Tian, Ying-Hong; Yang, Ya-Qi; Liu, Jing; Ma, Yu-Xin*Cell Death Discovery, 2023, 9(1): 15.被引 6
- Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer diseaseZhang, Wei; Wang, Jigang*; Yang, Chuanbin*Autophagy, 2022, 18(7): 1740-1742.被引 19
- Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potentialZhang, Wei; Xu, Chengchao; Sun, Jichao; Shen, Han-Ming*; Wang, Jigang*; Yang, Chuanbin*Acta Pharmaceutica Sinica B, 2022, 12(3): 1019-1040.被引 49
